NEW STUDY FINDS THE PLACENTA, NOT ONLY THE BRAIN, PLAYS A CENTRAL ROLE IN GENETIC RISK OF SCHIZOPHRENIA
Future Prevention Strategies Could Target Treatment of the Placenta
BALTIMORE, Md. (May 15, 2023) – More than 100 genes linked to the risk of schizophrenia seem to cause illness because of their role in the placenta rather than in the developing brain, according to a new study led by the Lieber Institute for Brain Development.
Journalists: For more information about the paper or to interview one of the scientists involved, please contact Katy Lenard at klenard[at]burness.com.
Scientists had generally assumed for over a century that genes for schizophrenia risk were principally, if not exclusively, about the brain. But the latest research, just published in Nature Communications, found that the placenta plays a much more significant role in developing illness than previously known. Read the full paper here.
“The secret of the genetics of schizophrenia has been hiding in plain sight—the placenta, the critical organ in supporting prenatal development, launches the developmental trajectory of risk,” says Daniel Weinberger, M.D., senior author of the paper and Director and CEO of the Lieber Institute for Brain Development, located on the Johns Hopkins medical campus in Baltimore. “The commonly shared view on the causes of schizophrenia is that genetic and environmental risk factors play a role directly and only in the brain, but these latest results show that placenta health is also critical.”
The researchers found that schizophrenia genes influence a critical function of the placenta to sense nutrients in the mother’s bloodstream, including oxygen, and exchange nutrients based on what it finds. The schizophrenia risk genes are more lowly expressed in the cells of the placenta that form the core of this maternal-fetal nutrient exchange, called trophoblasts, negatively affecting the placenta’s role in nurturing the developing fetus.
The paper also identifies several genes in the placenta that are causative factors for diabetes, bipolar disorder, depression, autism and attention deficit hyperactivity disorder, or ADHD. The scientists, however, found far more genetic associations with genes for schizophrenia than for any of these other disorders.
The researchers also discovered that the risk genes for schizophrenia found in the placenta may have a relatively greater effect on heritability, the likelihood of illness inherited from ancestors, than risk genes found in the brain.
“Targeting placenta biology is a crucial new potential approach to prevention, which is the holy grail of public health,” says Gianluca Ursini, M.D., Ph.D., the lead author on the paper and an investigator at the Lieber Institute. “Scientists could detect changes in placental risk genes decades before the possible onset of a disorder, possibly even in the mother’s bloodstream during pregnancy. If doctors knew which children were most at risk of developmental disorders, they could implement early interventions to keep them healthy.”
The scientists also found interesting sex-based differences in the placenta risk genes. Different genes were associated with schizophrenia risk based on whether the placenta came from a male or female child. In pregnancies with male children, inflammatory processes in the placenta seem to play a central role. Previous research has shown males are more vulnerable than females to prenatal stress. Generally speaking, developmental disorders such as schizophrenia occur more frequently in men and boys.
The researchers also uncovered concerning results about COVID-19 pregnancies. The scientists studied a small sample of placentas from mothers who had COVID-19 during pregnancy and found the schizophrenia genes for placenta risk were dramatically activated in these placentas. The finding indicates that COVID-19 infection during pregnancy may be a risk factor for schizophrenia because of how infection affects the placenta. Lieber Institute scientists are pursuing this possibility with NIH-funded research examining COVID-19 placentas to learn more.
The Lieber Institute researchers hope their ongoing study of the genes of the placenta will one day lead to new treatment and diagnostic tools, perhaps revolutionizing the field of prenatal medicine.
“In the modern era of molecular and genetic medicine, the standard treatment for a complicated pregnancy is still primarily bedrest,” says Dr. Weinberger. “These new molecular insights into how genes related to disorders of the brain and other organs play out in the placenta offer new opportunities for improving prenatal health and preventing complications later in life.”
About the Lieber Institute for Brain Development (LIBD)
The mission of the Lieber Institute for Brain Development and the Maltz Research Laboratories is to translate the understanding of basic genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances that change the lives of affected individuals. LIBD is an independent, not-for-profit 501(c)(3) organization and a Maryland tax-exempt medical research institute affiliated with the Johns Hopkins University School of Medicine. The Lieber Institute’s brain repository of more than 4,000 human brains is the largest collection of postmortem brains for the study of neuropsychiatric disorders in the world.